Monday, August 15, 2022

Perioperative Blood Transfusion in Head and Neck Cancer Revisited

alexandrossfakianakis shared this article with you from Inoreader
Perioperative Blood Transfusion in Head and Neck Cancer Revisited

In the past, blood transfusions in head and neck cancer patients were associated with high rates of complications and mortality. This retrospective study of 590 patients with surgical treatment of incident HNC was performed to identify transfusion triggers and analyze survival rates of transfused patients in times of restrictive transfusion regimens. During a time span of 10 years, 37 patients received blood transfusions, triggers were a high ASA score, low preoperative hemoglobin levels, long duration of surgery and p16 negativity, survival of transfused and matched non transfused patients was similar.


Objective

To reevaluate the frequency of perioperative blood transfusion, transfusion triggers, and survival impact in patients with incident, surgically treated head and neck cancer (HNC) in restrictive transfusion regimens.

Methods

Retrospective analysis of surgically treated patients with incident HNC with and without perioperative blood transfusion between 2008 and 2019 at the Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, according to the department's clinical Head and Neck Tumor Registry.

Results

Of the 590 patients included, perioperative transfusions were administered in 6.3% (n = 37, transfusion group). Following multivariable logistic regression, likelihood of blood transfusions was increased in patients with poorer general health conditions (ASA score III/IV; OR 3.7; 95% CI 1.9–8.6; p = 0.002), hemoglobin <12.5 g/dL (OR 2.7; 95% CI 1.1–6.4; p = 0.03), longer duration of surgery (OR 1.006 per minute of surgery time; 95% CI 1.003–1.008; p < 0.001), and negative p16 status (OR 5.3; 95% CI = 1.1–25; p = 0.03). Based on 14 matching variables related to survival and perioperative blood transfusion, a control group of 37 matching patients without perioperative transfusion was identified. Using univariate analysis, overall survival in transfusion and control groups did not differ significantly (p = 0.25). After adjusting for four parameters with limited ma tching accuracy (Chi square p < 0.2) in Cox regression analysis, a transfusion related hazard ratio close to 1 (HR 0.92; 95% CI 0.34–2.51; p = 0.87) was observed.

Conclusion

Considering current restrictive transfusion regimens and general transfusion risks, the administration of blood products in HNC patients during the perioperative period is not associated with additional oncologic hazard.

Level of Evidence

III Laryngoscope, 2022

View on Web

No comments:

Post a Comment

Collaboration request

Hi there How would you like to earn a 35% commission for each sale for life by selling SEO services Every website owner requires the ...